CytRx begins Phase 2 clinical trial with aldoxorubicin for Kaposi's sarcoma CytRx has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposiís sarcoma. The primary objective of preliminary efficacy will be determined through evaluation of the size, number and nodularity of skin lesions, and the company will evaluate the level of aldoxorubicin uptake into lesions. CytRx plans to discuss a pathway for the registration of aldoxorubicin for KS with the FDA if the data are positive. The company expects to announce data from this Phase 2 clinical trial in Q2 2015.
News For CYTR From The Last 14 Days
Check below for free stories on CYTR the last two weeks.